Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer.

Cancers (Basel) · 2020 · PMC7699469 · PMID 33228149

Europe PMC DOI

hedged sentence

0.0830

closest p · 1.7× alpha

0.0830

boldest claim

The sentences

did not reach statistical significancep = 0.083so close (0.05 < p ≤ 0.1)

However, the combination was more toxic than single-agent gemcitabine, since the frequency of grade ≥ 3 treatment-related adverse events was 69% with FOLFIRINOX and 60% with gemcitabine, even though this difference did not reach statistical significance ( p = 0.083).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.